Due to significant risks of cancer recurrence and progression, and limited options after intravesical Bacillus Calmette Guerin (BCG) therapy, there is a critical unmet need to identify novel treatments for those patients with BCG-unresponsive bladder cancer. There is active investigation of immunotherapies which provide both biologic and clinical rationales for indoleamine-2,3- dioxygenase inhibitors in salvage therapy for non-muscle invasive bladder cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ucl.2019.09.013 | DOI Listing |
Publication Analysis
Top Keywords
bladder cancer
12
inhibitors salvage
8
salvage therapy
8
therapy non-muscle
8
non-muscle invasive
8
invasive bladder
8
role indoleamine-23-dioxygenase
4
indoleamine-23-dioxygenase inhibitors
4
cancer
4
cancer risks
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!